Dr. O'Connor Discusses Regorafenib Dosing in mCRC

Juan Manuel O'Connor, MD
Published: Thursday, Nov 29, 2018



Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer (mCRC).

The final results from the prospective, observational CORRELATE study reported the real-world dosing data for regorafenib in patients with mCRC with the aim of addressing safety. Of the 2037 patients evaluated, results showed that 57% started treatment at 160 mg, 30% of patients began at 120 mg, and 13% began at ≤80 mg.

O’Connor says that these findings mean that there were many doctors who used a starting dose that was different than the recommended dose. He added that it is important to keep the ReDOS data in mind when discussing CORRELATE. The ReDOS study evaluated a dose-escalation strategy of regorafenib beginning at 80 mg and ending at 160 mg for previously treated patients with mCRC. Positive survival data led to the NCCN-recommended starting dose of regorafenib at 80 mg/daily on days 1 to 7, escalating to 120 mg/daily on days 8 to 14, and concluding with 160 mg/daily on days 15 to 21.
SELECTED
LANGUAGE


Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer (mCRC).

The final results from the prospective, observational CORRELATE study reported the real-world dosing data for regorafenib in patients with mCRC with the aim of addressing safety. Of the 2037 patients evaluated, results showed that 57% started treatment at 160 mg, 30% of patients began at 120 mg, and 13% began at ≤80 mg.

O’Connor says that these findings mean that there were many doctors who used a starting dose that was different than the recommended dose. He added that it is important to keep the ReDOS data in mind when discussing CORRELATE. The ReDOS study evaluated a dose-escalation strategy of regorafenib beginning at 80 mg and ending at 160 mg for previously treated patients with mCRC. Positive survival data led to the NCCN-recommended starting dose of regorafenib at 80 mg/daily on days 1 to 7, escalating to 120 mg/daily on days 8 to 14, and concluding with 160 mg/daily on days 15 to 21.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x